請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/32316
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李百祺 | |
dc.contributor.author | Tzu-Yin Wang | en |
dc.contributor.author | 王慈吟 | zh_TW |
dc.date.accessioned | 2021-06-13T03:42:25Z | - |
dc.date.available | 2006-07-31 | |
dc.date.copyright | 2006-07-31 | |
dc.date.issued | 2006 | |
dc.date.submitted | 2006-07-26 | |
dc.identifier.citation | [1] N. G. Rainov, “A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme,” Hum. Gene Ther., vol. 11, pp. 2389-2401, 2000.
[2] F. R. Khuri, J. Nemunaitis, I. Ganly, J. Arseneau, I. F. Tannock, L. Romel, M. Gore, J. Ironside, R. H. MacDougall, C. Heise, B. Randlev, A. M. Gillenwater, P. Bruso, S. B. Kaye, W. K. Hong and D. H. Kirn, “A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouricil in patients with recurrent head and neck cancer,” Nature Med., vol. 6, pp. 879-885, 2000. [3] B. Larsson, L. Leksell, B. Rexed, P. Sourander, W. Mair and B. Andersson, “The high-energy proton beam as a neurosurgical tool,” Nature, vol. 182, pp. 1222-1223, November 1958. [4] J. C. T. Chen and M. R Girvigian, “Stereotactic radiosurgery: instrumentation and theoretical aspects—part 1,” The Permanente Journal, vol.9, pp. 23-26, Fall 2005. [5] L. S. Goodman, M. M. Wintrobe, W. Dameshek, M. J. Goodman, A. Gilman and M. T. McLennan, “Nitrogen mustard therapy: Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia, and certain allied and miscellaneous disorders,” J Am Med Assoc, vol. 105, pp. 475-476, 1946. [6] J. F. Kerr, C. M. Winterford and B. V. Harmon, “Apoptosis: its significance in cancer and cancer therapy,” Cancer vol. 73 pp.2013-2026, April 1994. [7] E. Frei III, M. Karon, R. H. Levin, E. J. Freireich, R. J. Taylor, J. Hananian, O. Selawry, J. F. Holland, B. Hoogstraten, I. J. Wolman, E. Abir, A. Sawitsky, S. Lee, S. D. Mills, E. O. Burgert Jr., C. L. Spurr, R. B. Patterson, F. G. Ebaugh, G. W. James III and J. H. Moon, “The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia,” Blood, vol. 26, pp. 642-656, 1965. [8] P. S. Schein, B. A. Chabner, G. P. Canellos, R. C. Young, C. Berard and V. T. DeVita, “Potential for prolonged disease-free survival following combination chemotherapy of non-hodgkin’s lymphoma,” Blood, vol. 43, pp. 181-189, 1974. [9] J. Ragaz, S. M. Jackson, N. Le, I. H. Plenderleith, J. J. Spinelli, V. E. Basco, K. S. Wilson, M. A. Knowling, C. M. L. Coppin, M. Paradis, A. J. Coldman and I. A. Olivotto, “Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer,” vol. 337, pp. 956-962, October 1997. [10] G. Bonadonna, E. Brusamolino, P. Valagussa, A. Rossi, L. Brugnatelli, C. Brambilla, M. De Lena, G. Tancini, E. Bajetta, R. Musumeci and U. Veronesi, “Combination chemotherapy as an adjuvant treatment in operable breast cancer,” N. Engl. J. Med., vol. 294, pp. 405-410, 1976. [11] K. J. Stelzer, T. W. Griffin and W. J. Koh, “Radiation recall skin toxicity with bleomycin in a patient with Kaposi sarcoma related to acquired immune deficiency syndrome,” Cancer, vol. 71, pp. 1322-1325, 1993. [12] E. A. Perez, D. L. Campbell and J. K. Ryu, “Radiation recall dermatitis induced by edatrexate in a patient with breast cancer,” Cancer Invest., vol. 13, pp. 604-607, 1995. [13] H. Kitani, T. Kosaka, T. Fujihara, K. Lindquist and M. M. Elkind, “The 'recall effect' in radiotherapy: Is subeffective, reparable damage involved?” Int. J. Radiat. Oncol. Biol. Phys., vol. 18, pp. 689-695, 1990. [14] A. Kuten, H. Ben-Aryeh, I. Berdicevsky, L. Ore, R. Szargel, D. Gutman and E. Robinson, “Oral side effects of head and neck irradiation: Correlation between clinical manifestations and laboratory data,” Int. J. Radiat. Oncol. Biol. Phys., vol. 12, pp. 401-405, 1986. [15] A. K. Bronner and A. F. Hood, “Cutaneous complications of chemotherapeutic agents,” J. Am. Acad. Dermatol., vol. 9, pp. 645-663, 1983. [16] A. Coates, S. Abraham, S. B. Kaye, T. Sowerbutts, C. Frewin, R. M. Fox, M. H. Tattersall, “On the receiving end--patient perception of the side-effects of cancer chemotherapy” Eur J Cancer Clin Oncol., vol. 19, pp. 203-208, February 1983. [17] C.-C. Shen and P.-C. Li, 'Tissue harmonic image analysis based on spatial covariance,' IEEE Trans. Ultrason. Ferroelec. Freq. Control, vol. 48, pp. 1648-1656, 2001. [18] C.-C. Shen and P.-C. Li, 'Pulse-inversion-based fundamental fmaging for contrast detection,' IEEE Trans. Ultrason. Ferroelec. Freq. Control, vol. 50, pp. 1124-1133, September 2003. [19] C.-H. Li, A.-H. Liao, J.-A. Ho and P.-C. Li, “Pulse inversion fundamental imaging with liposome microbubbles at 25-50 MHz,” in Ultrasonics Symposium, 2005, p. 395. [20] S. M. Demos, H. Önyüsel, J. Gilbert, S. I. Roth, B. Kane, P. Jungblut, J. V. Pinto, D. D. McPherson and M. E. Klegerman, “In vitro targeting of antibody-conjugated echogenic liposomes for site-specific ultrasonic image enhancement,” J. Pharm. Sci., vol. 86, pp. 167-171, 1996. [21] S. M. Demos, H. Alkan-Onyuksel, B. J. Kane, K. Ramani, A. Nagaraj, R. Greene, M. Klegerman M and D. D. McPherson, “In vivo targeting of acoustically reflective liposomes for intravascular and transvascular ultrasonic enhancement,” J Am Coll Cardiol., vol. 33, pp. 867-75, March 1999. [22] N. T. Sanghvi and R. H. Hawes, “High-intensity focused ultrasound,” Gastrointest. Endosc. Clin. N. Am., vol. 4, pp. 383-395, Apr 1994. [23] J. E. Kennedy, G. R. ter Haar and D Cranston, “High intensity focused ultrasound: surgery of the future?” British Journal of Radiology, vol. 76, pp. 590–599, 2003. [24] J. G. Lynn, R. L. Zwemer, A. J. Chick and A. E. Miller, “A new method for the generation and use of focused ultrasound in experimental biology,” J. Gen. Physiol., vol. 26, pp. 179-193, 1942. [25] W. J. Fry, J. W. Barnard, F. J. Fry, R. F. Krumins and J. F. Brennan, “Ultrasonic lesions in the mammalian central nervous system,” Science, vol. 122, pp. 517–518, 1955. [26] F. J. Fry, “Precision high-intensity focusing ultrasonic machines for surgery,” Am. J. Phys. Med., vol. 37, pp. 152–156, 1958. [27] H. T. Ballantine, E. Bell and J. Manlapaz, “Progress and problems in the neurological application of focused ultrasound,” J. Neurosurg, vol. 17, pp. 858–876, 1960. [28] R. Warwick and J. B. Pond, “Trackless lesions in nervous tissues produced by HIFU (high-intensity mechanical waves),” J. Anat., vol. 102, pp. 387–405, 1968. [29] A. K. Burov, “High-intensity ultrasonic vibrations for action on animal and human malignant tumours,” Dokl Akad Nauk SSSR, vol. 106, pp.239–241, 1956. [30] K. Hynynen, “Review of ultrasound therapy,” in Ultrasonics symposium, 1997, pp. 1305-1313. [31] A. N. Gam and F. Johannsen, “Ultrasound therapy in musculoskeletal disorders: a meta-analysis,” Pain, vol. 63, pp. 85-91, 1995. [32] J. N. Kabalin, K. K. Hodge, J. E. McNeal, F. S. Freiha and T. A. Stamey, “Identification of residual cancer in the prostate following radiation therapy: role of transrectal ultrasound guided biopsy and prostate specific antigen,” J Urol., vol. 142, pp. 326-31, 1989. [33] R. Yang, C. R. Reilly, F. J. Rescorla, P. R. Faught, N. T. Sanghvi, F. J. Fry, T. D. Franklin Jr, L. Lumeng and J. L. Grosfeld, “High-intensity focused ultrasound in the treatment of experimental liver cancer,” Arch. Surg., vol. 126, pp. 1002-1009, 1991. [34] H. G. Flynn, “Generation of transient cavities in liquids by microsecond pulses of ultrasound,” J. Acoust. Soc. Am., vol. 72, pp. 1926-1932, 1982. [35] R. A. Roy and J. B. Fowlkes, “A comparison of the thresholds for free-radical generation and transient cavitation activity induced by short pulses of ultrasound,” J. Acoust. Soc. Am. Suppl. 1, vol. 84, pp. S36, 1988. [36] S. Vaezy, R. Martin, P. Mourad and L. Crum, “Hemostasis using high intensity focused ultrasound,” European Journal of Ultrasound, vol. 9, pp. 79-87, 1999. [37] J. E. Parsons, C. A. Cain and J. B. Fowlkes, “Characterizing Pulsed Ultrasound Therapy for Production of Cavitationally-Induced Lesions,” in Proc. International Symp. on Therapeutic Ultrasound, 2004, pp. 178-180. [38] B. C. Tran, J. Seo, T. L. Hall, J. B. Fowlkes and C. A. Cain, “Microbubble-enhanced cavitation for noninvasive ultrasound surgery,” IEEE Trans. Ultrason. Ferroelec. Freq. Control, vol. 50, pp. 1296-1304, 2003. [39] D. M. Skyba, R. J. Price, A. Z. Linka, T. C. Skalak and S. Kaul, “Direct in vivo visualization of intravascular destruction of microbubbles by ultrasound and its local effects on tissue,” Circulation, vol. 98, pp. 290-293, 1998. [40] S. Umemura, K. Kawabata and K. Sasaki, “Enhancement of sonodynamic tissue damage production by second-harmonic superimposition: theoretical analysis of its mechanism,” IEEE Trans. Ultrason. Ferroelec. Freq. Control, vol. 43, pp. 1054-1062, 1996. [41] E. C. Unger, E. Hersh, M. Vannan, T. O. Matsunaga and T. McCreery, “Local drug and gene delivery through microbubbles,” Prog. Cardiovasc. Dis., vol. 44, pp. 45-54, 2001. [42] S. Koch, P. Pohl, U. Cobet and N. G. Rainov, “Ultrasound enhancement of liposome-mediated cell transfection is caused by cavitation effects,” Ultrasound Med. Biol., vol. 26, pp. 897-903, 2000. [43] D. L. Miller and J. Song, “Lithotripter shock waves with cavitation nucleation agents produce tumor growth reduction and gene transfer in vivo,” Ultrasound Med Biol., vol. 28, pp. 1343-1348, 2002. [44] C. H. Miao, A. A. Brayman, K. R. Loeb, P. Ye, L. Zhou, P. Mourad and L. A. Crum, “Ultrasound enhances gene delivery of human factor IX plasmid,” Human Gene Therapy, vol. 16, pp. 893-905, 2005. [45] J. E. Chomas, P. Dayton, J. Allen, K. Morgan and K. W. Ferrara, “Mechanisms of contrast agent destruction,” IEEE Trans. Ultrason. Ferroelect. Freq. Contr., vol. 48, pp. 232-248, 2001. [46] M. S. Plesset and T.P. Mitchell, “On the stability of the spherical shape of a vapour cavity in a liquid,” Q. Appl. Math., vol. 13, pp. 419-430, 1956. [47] E. N. Harvey, D. K. Barnes, W. D. McElroy, A. H. Whiteley, D. C. Pease and K. W. Cooper, “Bubble formation in animals. I. physical factors,” J. Cell Comp. Physiol., vol. 24, pp. 1-22, 1944. [48] F. E. Fox and K. F. Herzfeld, “Gas bubbles with organic skin as cavitation nuclei,” J. Acoust. Soc. Am., vol. 26, pp. 984-989, 1954. [49] C. K. Holland and R. E. Apfel, “Thresholds for transient cavitation produced by pulsed ultrasound in a controlled nuclei environment,” J. Acoust. Soc. Am., vol. 88, pp. 2059-2069, 1990. [50] S. Umemura, K. Kawabata and K. Hashiba, “Enhancement of ultrasound absorption by microbubbles for therapeutic application,” in Ultrasonics Symposium, 2001, pp. 1311-1314. [51] R. Gramiak and P. M. Shah, “Echocardiography of the aortic root,” Invest. Radiol., vol. 3, pp. 356-366, Sep-Oct 1968. [52] M. C. Ziskin, A. Bonakdarpour, D. P. Weinstein and P. R. Lynch, “Contrast agents for diagnostic ultrasound,” Invest. Radiol., vol. 7, pp. 500-505, Nov-Dec 1972. [53] F. W. Kremkau, R. Gramiak, E. L. Carstensen, P. M. Shah and D. H. Kramer, “Ultrasonic detection of cavitation at catheter tips,” J. Acoust. Soc. Am., vol. 45, p. 340, Jan 1969. [54] S. B. Feinstein, P. M. Shah, R. J. Bing, S. Meerbaum, E. Corday, B. L. Chang, G. Santillan and Y. Fujibayashi, “Microbubble dynamics visualized in the intact capillary circulation,” J. Am. Coll. Cardiol., vol. 4, pp. 595-600, Sep 1984. [55] H. Becher and P. N. Burns, Handbook of Contrast Echocardiography. Secaucus, NJ: Springer, 2000, pp. 6-7. [56] A. F. Lum, M. A. Borden, P. A. Dayton PA, D. E. Kruse, S. I. Simon and K. W. Ferrara, “Ultrasound radiation force enables targeted deposition of model drug carriers loaded on microbubbles,” J. Control Release., vol. 111, pp. 128-134, Mar 2006. [57] R. E. Apfel and C. K. Holland, “Gauging the likelihood of cavitation from short-pulse, low-duty cycle diagnostic ultrasound,” Ultrasound Med. Biol., vol. 17, pp. 179-187, 1991. [58] R. E. Apfel, “Acoustic cavitation prediction,” J. Acoust. Soc. Am., Vol. 69, pp. 1624-1633, Jun 1981. [59] 賴寬裕, “以穴蝕效應為主之超音波治療, 誘發與偵測,” 國立台灣大學電機工程學研究所碩士論文, 民國九十三年. [60] 賴俊延, “超音波穴蝕效應於基因轉殖效率之研究” 國立台灣大學電機工程學研究所碩士論文, 民國九十四年. [61] X. Lu and P. Zhong, “Ultrasound-induced cell detachment and gene transfection in adherent cells,” Acoustics Research Letters Online, vol. 6, pp. 195-200, Jul 2005. [62] T. Fritzsch, M. Schartl and J. Siegert, “Preclinical and clinical results with an ultrasonic contrast agent,” Invest. Radiol., vol. 23, pp. S302-305, Sep 1988. [63] Levovist® Data Sheet, Schering AG. [64] F. Forsberg, W. T. Shi, C. R. B. Merritt, Q. Dai, M. Solcova, and B. B. Goldberg, “On the usefulness of the mechanical index displayed on clinical ultrasound scanners for predicting contrast microbubble destruction,” J. Ultrasound Med., vol. 24, pp.443-450, 2005. [65] L. Hoff, Acoustic Characterization of Contrast Agent for Medical Ultrasound Imaging. Trondheim, Norway, 2001. [66] W.-S. Chen, A. A. Brayman, T. J. Matula and L. A. Crum, “The pulse length-dependence of inertial cavitation dose and hemolysis,” Ultrasound Med. Biol., vol. 29, pp. 739-748, 2003. [67] P. A. Dayton, K. E. Morgan, A. L. Klibanov, G. H. Brandenburger and K. W. Ferrara, “Optical and acoustical observations of the effects of ultrasound oncontrast agents,” IEEE Trans. Ultrason. Ferroelec. Freq. Control, vol.46, pp. 220-232, Jan 1999. [68] R. A. Roy, S. I. Madanshetty and R. E. Apfel, “An acoustic backscattering technique for the detection of transient cavitation produced by microsecond pulses of ultrasound,” J. Acoust. Soc. Am., vol. 87, pp. 2451-2458, Jun 1990. [69] S. I. Madanshetty, R. A. Roy, R. E. Apfel, “Acoustic microcavitation: its active and passive acoustic detection,” J. Acoust. Soc. Am., vol. 90, pp. 1515-1526, Sep. 1991. [70] A. A. Atchley, L. A. Frizzell, R. E. Apfel, C. K. Holland, S. Madanshetty, R. A. Roy, “Thresholds for cavitation produced in water by pulsed ultrasound,” Ultrasonics, pp. 280-285, vol. 26, Sep 1988. [71] W.-S Chen, A. A. Brayman, T. J. Matula and L. A. Crum, “Inertial cavitation dose and hemolysis produced in vitro with or without Optison®,” Ultrasound Med. Biol., vol. 29, pp. 725-737, 2003. [72] C.-Y. Lai, C.-H. Wu, C.-C. Chen and P.-C. Li, “Quantitative relations between acoustic inertial cavitation and gene transfection rate/cell viability,” in Ultrasonics Symposium, 2005, p. 291. [73] H. Lodish, A. Berk, P. Matsudaira, C. A. Kaiser, M. Krieger, M. P. Scott, L. Zipursky, J. Darnell, Molecular Cell Biology. 4th Ed, New York: Freeman, 2000. [74] S. M. Demos, S. Dagar, M. Klegerman, A. Nagaraj, D. D. McPherson, H. Onyuksel, “In vitro targeting of acoustically reflective immunoliposomes to fibrin under various flow conditions,” J. Drug Target., vol. 5, pp. 507-518, 1998. [75] O. P. Medina, T. Söderlund, L. J. Laakkonen, E. K. J. Tuominen, E. K. and P. K. J. Kinnunen, “Binding of novel peptide inhibitors of type iv collagenases to phospholipid membranes and use in liposome targeting to tumor cells in vitro,” Cancer Research, vol. 61, pp. 3978-3985, May 2001. [76] D. C. Drummond, K. Hong, J. W. Park, C. C. Benz and D. B. Kirpotin, “Liposome targeting to tumors using vitamin and growth factor receptors,” Vitam. Horm., vol. 60, pp. 285-332, 2000. [77] F. Umezawa and Y. Eto, “Liposome targeting to mouse brain: mannose as a recognition marker,” Biochem Biophys Res Commun., vol. 153, pp. 1038-1044, Jun 1988. [78] A. Huang, L. Huang and S. J. Kennel, “Monoclonal antibody covalently coupled with fatty acid. A reagent for in vitro liposome targeting,” J. Biol. Chem., vol. 255, pp. 8015-8018, Sep 1980. [79] R. M. Hoffman, “Topical liposome targeting of dyes, melanins, genes, and proteins selectively to hair follicles,” J. Drug Target., vol. 5, pp. 67-74, 1998. [80] H. Alkan-Onyuksel, S. M. Demos, G. M. Lanza, M. J. Vonesh, M. E. Klegerman, B. J. Kane, J. Kuszak and D. D. Mcpherson, “Development of inherently echogenic liposomes as an ultrasound contrast agent,” J. Pharm. Sci., vol. 85, pp. 486-490, May 1996. [81] H. Ashush, L. A. Rozenszajn, M. Blass, M. Barda-Saad, D. Azimov, J. Radnay, D. Zipori and U. Rosenschein, “Apoptosis Induction of Human Myeloid Leukemic Cells by Ultrasound Exposure,” Cancer Research, vol. 60, pp. 1014–1020, 2000. [82] L. Hoff, P. C. Sontum and J. M. Hovem, “Oscillations of polymeric microbubbles: Effect of the encapsulating shell,” J. Acoust. Soc. Am., vol. 107, pp. 2272-2280, 2000. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/32316 | - |
dc.description.abstract | 穴蝕效應是超音波誘使氣泡形成至破裂的過程,此過程釋出之能量可能引起嚴重的生物效應,因此造影用超音波之強度和能量均受到嚴格監控,以避免對人體組織不當的損傷。但是若能侷限穴蝕效應於患部,利用釋出的能量破壞腫瘤細胞或輔助藥物傳遞,穴蝕效應有潛力成為專一性治療之工具,並且可以有效與現有之超音波影像系統結合。因此,本研究終極目標是結合超音波影像與治療,在造影安全規範下,藉由微氣泡的輔助,有效誘發穴蝕效應,達成腫瘤治療之目的。
本研究之主要工作如下:首先我們量化評比數種波形誘發之穴蝕效應劑量,在固定機械參數於0.06~0.79之範圍內,測試總脈衝周數為10周的1.5MHz、3MHz和串接波形誘發的慣性穴蝕劑量。結果顯示相同機械參數的三種波形可誘發不同程度的穴蝕效應,可能原因之一為機械參數主要是預測自由氣泡之破裂,而本實驗的氣泡皆是有殼氣泡;原因之二是機械參數代表穴蝕效應發生的門檻,卻無法預測穴蝕效應之程度。故機械參數或許並非評估此類氣泡之穴蝕效應的最佳指標,而單以機械參數作為穴蝕效應之安全規範亦有再檢討之必要。 完成定量分析之後,本研究進一步將此技術應用到離體實驗,觀察穴蝕效應破壞腫瘤細胞之能力。由於活體內穴蝕核數量少且分布不均,不利於掌控穴蝕效應,為了能夠降低穴蝕效應之門檻,並且針對患部做專一性治療,在離體實驗部分,本研究將使用實驗室自製微脂體做為穴蝕核。微脂體有諸多發展潛力,微脂體表面傳輸定位抗體及修飾標定可使微脂體具有靶向性,可與特定組織進行專一性結合,應用在治療上,積聚在靶區的微脂體可提供微氣泡,增強靶區穴蝕效應,達到靶向治療之功能;應用在造影方面,微脂體可作為高頻超音波影像之對比劑與分子探針,協助分子影像技術之開發。我們已經可以製作包覆空氣之微脂體,並且以影像亮度法定性分析微脂體輔助之穴蝕效應,以慣性穴蝕效應劑量方法定量分析穴蝕效應劑量,建立穴蝕效應劑量與微脂體濃度、發射聲壓與脈衝長度之關聯。我們更進一步將自製微脂體用於離體實驗測試,建立離體實驗之架構以誘發穴蝕效應,並觀察細胞死亡率之變化。 離體實驗中,我們針對MKN45細胞株測試穴蝕效應對癌症細胞的破壞,目前由於微脂體對於實驗干擾仍未去除,尚未觀察到穴蝕效應引發之顯著癌細胞破壞,未來將改良自製微脂體之配方與製程,增加有效穴蝕核數量並加強控制微脂體品質,期能輔助增強穴蝕效應。此外也將最佳化超音波參數,選定合適頻率以及設計特殊波形以增強穴蝕效應,改進破壞腫瘤細胞之能力。離體實驗之後,我們將展開活體實驗,以活體微透析探針與微光纖系統,非侵入式即時觀察腫瘤治療效果。 | zh_TW |
dc.description.abstract | Cavitation is the phenomena where cavities form and rapidly collapse within a liquid under intense pressure changes. The energy emitted during the cavitation process is likely to induce tissue damage. Therefore, the safety regulations for diagnostic ultrasound have been carefully established to minimize the risk of cavitational bioeffects. Nevertheless, well-controlled acoustic cavitation can also be an effective tool for noninvasive cancer therapy.
Our long-term goal is to integrate ultrasound diagnosis and therapy- to achieve localized cancer treatment by microbubble-assisted cavitation under safety regulations. This study is the first step to the long-term job. The inertial cavitation doses (ICDs) are measured and studied at a constant mechanical index (MI). The MIs vary from 0.06 to 0.79. The ICDs induced by 1.5-MHz signals, 3-MHz signals and a signal cascading a 3-MHz signal with a 1.5-MHz signal are not equal even if the three waveforms have the same MIs. It is believed that the is due to the fact that MI was defined on cavitation activities of free gas bubbles, but encapsulated bubbles were used in our experiments. Another reason is that MI is not directly related to the degree and amount of cavitation as ICD. As a result, MI may not be the best index to quantify acoustic cavitation. The use of MI as the only parameter to represent potential cavitation-induced tissue damage is also questionable and requires further investigation. The in-house liposome microbubbles were used in the in vitro study on cavitational bioeffects. The quantitative study of liposome-assisted cavitation was conducted. An experimental system was built for the observation of the cavitation-induced cell damage to the human gastric cancer cell line, MKN45. Current results did not indicate a significant cavitation-induced cell death after one-minute exposure to ultrasound. In the future, the ultrasound parameters need to be optimized and the recipe of the in-house liposome microbubbles also needs to be improved for higher stability and stronger ICD. The in vivo study will follow the in vitro experiments. A microdialysis perfusion system and a microlight-guide system will be used to monitor the efficacy of in vivo tumor treatment. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T03:42:25Z (GMT). No. of bitstreams: 1 ntu-95-R93921053-1.pdf: 1728611 bytes, checksum: f1891480917813584475d5dcfbc6b878 (MD5) Previous issue date: 2006 | en |
dc.description.tableofcontents | 第一章 緒論 1
1.1前言 1 1.2超音波治療 3 1.3穴蝕效應與穴蝕核 5 1.4機械參數 8 1.5研究動機與目標 10 1.6論文架構 12 第二章 實驗材料與方法 13 2.1穴蝕效應實驗—誘發與偵測 13 2.1.1實驗系統架構 13 2.1.2穴蝕核 14 2.1.3穴蝕效應之誘發 16 2.1.3.1發射聲場校正 17 2.1.3.2聲波頻率 20 2.1.3.3脈衝長度 20 2.1.3.4特殊波形 21 2.1.3.5機械參數 22 2.1.4穴蝕效應之偵測 23 2.1.4.1 B-mode影像觀察法 23 2.1.4.2穴蝕效應之定量表示—Inertial Cavitation Dose 24 2.2細胞破壞實驗 28 2.2.1系統架構與實驗流程 28 2.2.2穴蝕核 30 2.2.3細胞株 34 2.2.4發射聲波參數 35 2.2.4.1發射聲場校正 35 2.2.4.2實驗參數 35 2.2.5細胞存活率量測法 36 第三章 實驗結果 37 3.1以穴蝕效應劑量方法評估機械參數之適用性 37 3.1.1聲波頻率 vs. 穴蝕效應 37 3.1.2脈衝長度vs. 穴蝕效應 37 3.1.3特殊波形vs. 穴蝕效應 38 3.1.4機械參數vs. 穴蝕效應 40 3.2自製微脂體之穴蝕效應實驗結果 41 3.2.1 B-mode影像觀察法 41 3.2.2微脂體濃度 vs. 穴蝕效應 41 3.2.3發射聲壓vs. 穴蝕效應 42 3.2.4脈衝長度vs. 穴蝕效應 43 3.3細胞破壞實驗結果 44 3.3.1微脂體濃度 vs. 細胞存活率 44 3.3.2發射聲壓 vs. 細胞存活率 45 3.3.3脈衝長度 vs. 細胞存活率 46 第四章 分析與討論 47 4.1機械參數與穴蝕效應之關聯 47 4.2以自製微脂體為穴蝕核之穴蝕效果分析 49 4.3細胞破壞實驗結果分析 52 第五章 結論與未來工作 54 第六章 參考文獻 58 | |
dc.language.iso | zh-TW | |
dc.title | 微氣泡輔助之穴蝕效應與超音波治療之應用 | zh_TW |
dc.title | Microbubble-assisted Cavitation and Its Application to Ultrasonic Therapy | en |
dc.type | Thesis | |
dc.date.schoolyear | 94-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 陳炯東,羅履維,江惠華,王士豪 | |
dc.subject.keyword | 超音波,微氣泡,穴蝕效應,機械參數,慣性穴蝕劑量,腫瘤細胞破壞, | zh_TW |
dc.subject.keyword | ultrasound,microbubbles,cavitation,mechanical index,inertial cavitation dose,cell toxicity, | en |
dc.relation.page | 66 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2006-07-26 | |
dc.contributor.author-college | 電機資訊學院 | zh_TW |
dc.contributor.author-dept | 電機工程學研究所 | zh_TW |
顯示於系所單位: | 電機工程學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-95-1.pdf 目前未授權公開取用 | 1.69 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。